Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global sales of the empty capsule market are expected to create lucrative growth opportunities over the projection period from 2022 to 2026 with a CAGR of 8%. The global market is expected to reach around $2.1B in 2022 and surpass a valuation of $2.9B by 2026.
read more
Agilent Technology announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the core of Agilent’s dissolution business, including research and development, quality, support, applications, marketing, and more.
read more
The global vegan supplements market reached a value of $6.9B in 2021, with an anticipated value of $10.88B by 2027, exhibiting a CAGR of 7.7% during 2021-2027, according to a Research & Markets report.
read more
Rising application of collagen peptide & gelatin from nutraceutical and functional food manufacturers is driven by awareness of their beneficial health effects, and rapidly expanding end-use industries will boost the collagen peptide and gelatin market size, according to a report by Transparency Market Research.
read more
Driven by R&D in the pharma sector and growth in the nutraceutical space, the tablets coating market is projected to reach $969M by 2025 from $739M in 2020, at a CAGR of 5.6% during the forecast period, according to a report by Markets and Markets.
read more
The global Reiter's syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027, according to a report from Research & Markets.
read more
Celanese Corporation, a global chemical and specialty materials company, ]announced an investment in expanded capabilities to meet high global demand for pharmaceutical-grade polymers used in the development of implants and inserts for sustained-release drug delivery.
read more
Ashland announced the launch of Klucel™ xtend HPC, as an extended release “former” excipient. The reduced polymer concentration achievable with Klucel™ xtend HPC offers the possibility of smaller pills or higher dosage.
read more
Ascletis Pharma announced dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 at the National Medical Center for Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University.
read more
Wellbeing Digital Sciences announced that subsidiary KGK Sciences applied for a phase 2A microdose psilocybin trial for fragile X syndrome for its client, Nova Mentis Life Science.
read more
Keystone Folding Box Co., a designer and manufacturer of paperboard
packaging products, has completed a two-year, $5M upgrade to its manufacturing
facility in Newark, New Jersey.
read more
Cambrex announced the expansion of their stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries.
read more
Government agencies investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy is driving growth, according to a Report by Research & Markets.
read more
Government agencies are funding academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy, which is expected to drive the market growth, according to a report by Research & Markets.
read more
Taiho Oncology and Taiho Pharmaceutical Co. announced that the U.S. Food and Drug Administration (FDA) has approved LYTGOBI® tablets for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or ...
read more